Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03491904 | To Assess the Patients' Ability to Self-Administer Fasinumab | PHASE1 | COMPLETED | 100 | — | — | Jan 23, 2019 | Dec 15, 2020 | Mar 3, 2021 | 23 | United States |
| Arm | Type | Description |
|---|---|---|
| Auto-injector (AI) | EXPERIMENTAL | - |
| Prefilled syringe (PFS) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fasinumab AI | DRUG | Self-administered with auto injector |
| Fasinumab PFS | DRUG | Prefilled syringe administered by study staff |
Key Inclusion Criteria: 1. A clinical diagnosis of Osteoarthritis (OA) of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2 for the index joint) at the screening visit 2. Moderate-to-severe pain in the index joint defined as a WOMAC ...